704906-68-3

Upstream product

• 704906-91-2 [1-(2-benzyloxy-4-benzyloxymethyl-6-nitro-benzyl)-3-iodo-prop-2-ynyloxy]-tert-butyl-dimethyl-silane 
• 704906-88-7 [1-(2-benzyloxy-4-benzyloxymethyl-6-nitro-benzyl)-prop-2-ynyloxy]-tert-butyl-dimethyl-silane 
• 704906-80-9 {3-benzyloxy-4-[2-(tert-butyl-dimethyl-silanyloxy)-4-trimethylsilanyl-but-3-ynyl]-5-nitro-phenyl}-methanol 
• 704906-60-5 3-benzyloxy-4-[2-(tert-butyl-dimethyl-silanyloxy)-4-trimethylsilanyl-but-3-ynyl]-5-nitro-benzoic acid methyl ester 
• 704906-84-3 {3-benzyloxy-4-[2-(tert-butyl-dimethyl-silanyloxy)-but-3-ynyl]-5-nitro-phenyl}-methanol 
• 704906-38-7 3-Benzyloxy-4-((R)-2-hydroxy-4-trimethylsilanyl-but-3-ynyl)-5-nitro-benzoic acid methyl ester 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 100-39-0 benzyl bromide 
• 201230-82-2 carbon monoxide 

Relevant academic research and scientific papers

Development of a flexible strategy towards FR900482 and the mitomycins

FR900482 and the mitomycins are two intriguing classes of alkaloid natural products that have analogous biological mechanisms and obvious structural similarity. Both classes possess potent anticancer activity, a feature that has led to their investigation